Skip to main content
Evidence Snapshot

Hepatocyte

CHEMBL613362 CELL-LINE Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613362
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatocyte as ChEMBL target CHEMBL613362. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatocyte
CELL-LINE · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL613362
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Hepatocyte matters

As of 2026-09-13

Hepatocyte is reviewed as Hepatocyte; the current evidence base includes 7 approved drugs, 2152 compounds, and 587 assays, with lead potency reaching pChEMBL 10.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 2152 compounds, and 587 assays for this target. The dominant activity type is IC50. CHEMBL1782559 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL1782559 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Hepatocyte matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2152
Total Compounds
587
Total Assays
7
Approved Drugs
IC50: 406.0, EC50: 27.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1782559
 10.0 IC50 —
No preferred name
CHEMBL1782557
 10.0 IC50 —
No preferred name
CHEMBL1782554
 10.0 IC50 —
No preferred name
CHEMBL1782552
 10.0 IC50 —
No preferred name
CHEMBL398240
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
ROSUVASTATIN
CHEMBL1496
 2003
CERIVASTATIN
CHEMBL1477
 1997
ATORVASTATIN
CHEMBL1487
 1996
SIMVASTATIN
CHEMBL1064
 1991
PRAVASTATIN
CHEMBL1144
 1991
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613362